Asunto(s)
Adenosina/efectos adversos , Enfermedad de la Arteria Coronaria/diagnóstico , Infarto del Miocardio/inducido químicamente , Vasodilatadores/efectos adversos , Adenosina/farmacología , Agonistas del Receptor de Adenosina A2/farmacología , Anciano , Enfermedad de la Arteria Coronaria/fisiopatología , Endotelio Vascular/efectos de los fármacos , Femenino , Humanos , Infarto del Miocardio/diagnóstico , Infarto del Miocardio/fisiopatología , Imagen de Perfusión Miocárdica , Receptor de Adenosina A2A/efectos de los fármacos , Tomografía Computarizada de Emisión de Fotón Único , Vasodilatación/efectos de los fármacos , Vasodilatadores/farmacologíaRESUMEN
Cell transplantation is an innovative technology that involves the implantation of a variety of myogenic and angiogenic cell types. The transplanted cells proliferate and augment left ventricular performance and therein ameliorate the heart failure symptoms. The concept of cell transplantation has followed the footsteps of angiogenesis starting as bench side research. The latter half of the decade saw the transformation of this potential mechanism to a promising therapy for ischemic heart failure. More than 150 patients have been treated with cellular transplantation worldwide. This novel application has the potential to revolutionize alternative therapeutic approaches to management of heart failure.
Asunto(s)
Trasplante de Células , Isquemia Miocárdica/complicaciones , Disfunción Ventricular Izquierda/cirugía , Animales , Trasplante de Médula Ósea , Cateterismo Cardíaco , Técnicas de Cultivo de Célula/métodos , Supervivencia Celular , Electrocardiografía , Técnicas Electrofisiológicas Cardíacas , Humanos , Miocitos Cardíacos/fisiología , Neovascularización Fisiológica/fisiología , Recuperación de la Función , Trasplante de Células Madre , Disfunción Ventricular Izquierda/diagnóstico , Disfunción Ventricular Izquierda/etiología , Disfunción Ventricular Izquierda/fisiopatología , Remodelación VentricularRESUMEN
Cardiovascular disease (CVD) in the developed countries continues to grow at an epidemic proportion. There are a significant number of young adults with no clinical evidence of CVD, but who have two or more risk factors that predispose them to CV events and death. Many of these risk factors are modifiable, and by controlling these factors, the CVD burden can be decreased significantly. Recent statistics have shown that, if all major forms of CVD were eliminated, the life expectancy would rise by almost 7 years. Hence it is imperative that primary prevention efforts should be initiated at a young age to avert decades of unattended risk factors. Hyperlipidemia has been linked to CVD almost a century ago. Since then various clinical trials have not only supported this link, but have also shown the CV benefits in aggressively treating patients with hyperlipidemia. In this generation, we have various therapeutic agents that are capable of reducing the elevated lipid levels. With drugs like statins, we are able to reduce the risk of CVD by about 30% and avoid major adverse events. Newer drugs are being researched and introduced in the treatment of hyperlipidemia in humans. These can be used in combination therapy resulting in optimal levels of lipids. The new National Cholesterol Education Program (NCEP)/Adult Treatment Panel III (ATP III) guidelines have come as a wake-up call to clinicians about primary prevention of CVD through strict lipid management and multifaceted risk management approach in the prevention of CVD.
Asunto(s)
Enfermedades Cardiovasculares/prevención & control , Hiperlipidemias/tratamiento farmacológico , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Hipolipemiantes/uso terapéutico , Prevención PrimariaRESUMEN
The prevalence of ischemic heart disease (IHD) has been increasing among the women in developed countries. The well recognized IHD excess in men has often obscured the fact that IHD is the leading cause of death in women. Women have atypical symptoms of IHD that lead to a delay in the diagnosis and an overall poor prognosis. Women have a delay in the onset of IHD due to the beneficial effects of their sex hormones. Postmenopausal women lose this beneficial effect of estrogen and undergo significant changes in their lipid profile, arterial pressure, glucose tolerance, and vascular reactivity that increase their risk for development of IHD. Recently there has been considerable interest in the sex hormones and their role in IHD in women. The general belief that hormone replacement therapy (HRT) has an overall beneficial effect on cardiovascular disease (CVD) in women and hence decreases CVD mortality and morbidity has not been shown in the recent multicenter prospective studies. With the availability of various types of estrogen and progestins, physicians prescribing these agents should take into consideration their varying effects on the cardiovascular system. Risk factor modifications should include diet, weight loss, regular exercise, smoking cessation and adequate control of hypertension (HTN), diabetes (DM) and hyperlipidemia. In the appropriate setting, treatment with proven beneficial agents like aspirin, beta-blockers, angiotensin converting enzyme (ACE) inhibitors and statins will help decrease the burden of IHD in women.
Asunto(s)
Terapia de Reemplazo de Estrógeno , Estrógenos/fisiología , Isquemia Miocárdica/fisiopatología , Animales , Anticonceptivos Hormonales Orales/farmacología , Terapia de Reemplazo de Estrógeno/efectos adversos , Femenino , Humanos , Isquemia Miocárdica/etiología , Progesterona/fisiología , Factores de Riesgo , Moduladores Selectivos de los Receptores de Estrógeno/farmacología , Factores SexualesRESUMEN
We report a case of successful treatment of a severely diseased saphenous vein graft from the transradial approach. Initial rheolytic thrombectomy was performed followed by coronary stenting through a 6 French guide catheter. Continuing miniaturization of interventional devices increases the utility of the transradial approach.
Asunto(s)
Puente de Arteria Coronaria , Estenosis Coronaria/cirugía , Vena Safena/trasplante , Stents , Trombectomía , Anciano , Implantación de Prótesis Vascular/instrumentación , Estenosis Coronaria/complicaciones , Humanos , Masculino , Trombectomía/métodos , Disfunción Ventricular Izquierda/complicaciones , Disfunción Ventricular Izquierda/cirugíaRESUMEN
The present study prospectively evaluated adjunctive antiplatelet therapy in patients without insulin-requiring diabetes during elective coronary stenting. Three hundred patients were randomized to one of three treatment groups: clopidogrel pretreatment, adjunctive abciximab, or control. Stenting was successful in 98% and no deaths occurred. Thirty-day and 1-year major adverse coronary events (MACEs) was similar in all groups. A subgroup of 109 patients undergoing single-vessel stenting of type A/B1 lesions with short guidewire times had no postprocedure myocardial infarction or 30-day MACE. We conclude that patients with these characteristics may safely undergo elective coronary stenting without adjunctive antiplatelet therapy.